A Study to Compare the Efficacy and Safety of Once Daily QVA149 Versus the Once Daily Concurrent Administration of QAB149 Plus NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2016
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Glycopyrrolate; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms BEACON
- Sponsors Novartis
- 23 Sep 2013 Data from this trial contributed to the approval of glycopyrrolate/indacaterol, delivered via the Ultibro Breezhaler, by the European Commission according to a Vectura Group media release.
- 11 Sep 2013 Lung function results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Tolerability results presented at the 23rd Annual Congress of the European Respiratory Society.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History